机构:[1]Department of Graduate School, Hebei Medical University, Shijiazhuang, China.[2]Department of Surgery and Urology, Hebei General Hospital, Shijiazhuang, China.[3]Department of Rheumatology and Immunology, Hebei General Hospital, Shijiazhuang, China.[4]YETEM Biotechnology Hebei Corporation, Ltd., Zhengding Area of Hebei Free Trade Zone, Shijiazhuang, China.[5]Department of Urology Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang City, Hebei, China.临床科室泌尿外科河北医科大学第四医院[6]Department of Surgery, Department of Oncology & Immunotherapy, Hebei General Hospital, Shijiazhuang, China.
第一作者机构:[1]Department of Graduate School, Hebei Medical University, Shijiazhuang, China.[2]Department of Surgery and Urology, Hebei General Hospital, Shijiazhuang, China.
通讯作者:
通讯机构:[1]Department of Graduate School, Hebei Medical University, Shijiazhuang, China.[4]YETEM Biotechnology Hebei Corporation, Ltd., Zhengding Area of Hebei Free Trade Zone, Shijiazhuang, China.[6]Department of Surgery, Department of Oncology & Immunotherapy, Hebei General Hospital, Shijiazhuang, China.[*1]Department of Graduate School, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang 050017, China
推荐引用方式(GB/T 7714):
Guo Liuxiong,Liu Yixuan,Yang Tao,et al.CAV1 and KRT5 are potential targets for prostate cancer[J].MEDICINE.2023,102(49):e36473.doi:10.1097/MD.0000000000036473.
APA:
Guo Liuxiong,Liu Yixuan,Yang Tao,Wang Gang,Liu Junjiang...&Cai Jianhui.(2023).CAV1 and KRT5 are potential targets for prostate cancer.MEDICINE,102,(49)
MLA:
Guo Liuxiong,et al."CAV1 and KRT5 are potential targets for prostate cancer".MEDICINE 102..49(2023):e36473